Company research
Immix Biopharma, Inc.
CIK 1873835Updated Nov 14, 2026
SecurityIMMX · NASDAQ · equity
Name history
Immix Biopharma, Inc. · through Nov 12, 2026
IMMX price & chart
Loading TradingView…
NASDAQ:IMMX on TradingView ↗About the company
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX ↗
Seeking Alpha
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript ↗
Immix rises after new mid-stage trial data for AL amyloidosis therapy ↗
Immix Biopharma prices $125M stock offering ↗
SEC disclosures
Immix Biopharma, Inc. files 8-K: Material Event ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Other Events
Items 8.01, 9.01
FWP - filed by Immix Biopharma, Inc. regarding Immix Biopharma, Inc.
424B5 filing
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 20,080,604Source | 25,141,552Source | 239,108,896Source | 15,635,104Source | 28,835,944Source | 95,816,057Source | 19,892,040Source | 34,347,592Source | 104,840,341Source | 22,947,872Source | 19,925,160Source | 14,908,101Source |
| Property, Plant and Equipment, NetUSD | 2,358,783Source | 1,355,424Source | 2,358,428Source | 2,231,517Source | 454,029Source | 2,428,377Source | 2,123,934Source | 360,834Source | 2,521,621Source | 1,740,149Source | 50,181Source | 3,560Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,947,308Source | 19,690,431Source | 225,491,985Source | 11,637,945Source | 23,975,098Source | 79,250,163Source | 15,921,101Source | 29,319,233Source | 93,928,566Source | 17,681,954Source | 17,509,791Source | 13,436,714Source |
| Assets, CurrentUSD | 16,584,280Source | 22,755,505Source | 233,790,071Source | 12,325,460Source | 27,330,835Source | 92,274,811Source | 16,779,244Source | 32,915,262Source | 101,237,755Source | 20,197,834Source | 19,787,750Source | 14,897,817Source |
| Prepaid Expense and Other Assets, CurrentUSD | 636,972Source | 1,089,637Source | 1,682,918Source | 687,515Source | 1,375,461Source | 1,695,649Source | 858,143Source | 1,571,303Source | 828,329Source | 541,510Source | 1,105,776Source | 1,205,398Source |
| Operating Lease, Right-of-Use AssetUSD | 1,005,434Source | 1,010,205Source | 887,837Source | 947,103Source | 1,030,662Source | 927,728Source | 968,444Source | 1,051,078Source | 966,917Source | 989,471Source | — | — |
| Other Assets, NoncurrentUSD | 20,418Source | 20,418Source | 20,418Source | 20,418Source | 20,418Source | 20,418Source | 20,418Source | 20,418Source | 20,418Source | 20,418Source | — | 6,724Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 11,815,634Source | 7,590,841Source | 10,192,343Source | 10,982,073Source | 4,944,723Source | 11,452,001Source | 10,298,487Source | 6,715,729Source | 11,044,171Source | 9,696,669Source | 3,721,783Source | 1,748,296Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,311Source | 2,757Source | 7,160Source | 2,847Source | 2,752Source | 5,307Source | 2,793Source | 2,648Source | 5,301Source | 2,762Source | 2,000Source | 1,397Source |
| Additional Paid in CapitalUSD | 102,074,612Source | 87,668,483Source | 354,997,609Source | 90,874,877Source | 86,934,682Source | 198,903,047Source | 89,242,459Source | 86,593,132Source | 198,293,956Source | 88,374,131Source | 69,779,706Source | 51,156,597Source |
| Retained Earnings (Accumulated Deficit)USD | -93,775,454Source | -70,212,617Source | -126,106,973Source | -86,189,762Source | -63,063,222Source | -114,549,971Source | -79,567,199Source | -58,670,286Source | -104,463,284Source | -75,024,671Source | -53,411,295Source | -37,985,247Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 62,464Source | 192,051Source | 118,720Source | 65,032Source | 116,972Source | 105,636Source | 15,463Source | 89,614Source | 60,160Source | -1,056Source | 134,666Source | 87,021Source |
| Stockholders' Equity Attributable to ParentUSD | — | 17,550,711Source | 228,916,553Source | 4,653,031Source | 23,891,221Source | 84,364,056Source | 9,593,553Source | 27,915,145Source | — | 13,251,203Source | 16,405,114Source | — |
| Liabilities and EquityUSD | 20,080,604Source | 25,141,552Source | 239,108,896Source | 15,635,104Source | 28,835,944Source | 95,816,057Source | 19,892,040Source | 34,347,592Source | 104,840,341Source | 22,947,872Source | 19,925,160Source | 14,908,101Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,850,581Source | 6,564,501Source | 9,301,705Source | 10,009,738Source | 3,901,920Source | 10,539,658Source | 9,307,361Source | 5,656,785Source | 10,110,546Source | 8,687,118Source | 3,721,783Source | 1,273,296Source |
| Operating Lease, Liability, CurrentUSD | 141,282Source | 62,715Source | 111,114Source | 70,467Source | 48,359Source | 125,392Source | 67,817Source | 34,284Source | 139,339Source | 65,219Source | — | — |
| Accounts Payable, CurrentUSD | 7,050,462Source | 3,288,579Source | 5,280,229Source | 6,614,389Source | 2,346,649Source | 4,730,152Source | 5,742,091Source | 3,512,950Source | 5,442,737Source | 5,388,494Source | 1,433,022Source | — |
| Operating Lease, Liability, NoncurrentUSD | 965,053Source | 1,026,340Source | 890,638Source | 972,335Source | 1,042,803Source | 912,343Source | 991,126Source | 1,058,944Source | 933,625Source | 1,009,551Source | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | -283,282Source | — | — | -201,737Source | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 232,100,000Source | — | — | 90,600,000Source | — | — | 100,400,000Source | — | — | — |
| Short-term InvestmentsUSD | — | — | 6,615,168Source | — | — | 11,328,999Source | — | — | 6,480,860Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -7,585,692Source | -7,149,395Source | — | -6,622,563Source | -10,100,000Source | -4,542,528Source | -29,438,613Source | -21,698,363Source | -15,595,522Source | -8,229,713Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 575,565Source | 868,359Source | 2,441,875Source | 3,020,573Source | 2,565,708Source | 524,069Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -9,827,193Source | -1,685,140Source | -23,930,304Source | -14,595,102Source | -11,371,438Source | -7,408,303Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -4,800,836Source | -67,713Source | -7,213,785Source | -1,177,680Source | -52,089Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 32,486Source | 67,713Source | 732,925Source | 1,177,680Source | 52,089Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 99,963Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -37,561Source | — | 107,386,859Source | 15,948,567Source | 15,463,512Source | 3,232,063Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -14,678,403Source | -1,760,853Source | 76,246,612Source | 172,163Source | 4,073,077Source | -4,207,764Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 9,596Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -12,813Source | -8,000Source | 3,842Source | -3,622Source | 33,092Source | -31,524Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 731,329Source | 476,746Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | 232,100,000Source | — | 90,600,000Source | — | 100,400,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | 90,993Source | 58,494Source | 91,577Source | 38,153Source | 245,747Source | 32,941Source | 5,468Source | 2,135Source |
| General and Administrative ExpenseUSD | — | — | 3,078,378Source | 2,949,403Source | 7,123,171Source | 2,745,247Source | 4,823,378Source | 2,707,851Source | 13,697,817Source | 11,381,978Source | 7,406,082Source | 4,023,170Source |
| Income Tax Expense (Benefit)USD | — | — | 7,722Source | 11,144Source | 14,322Source | 8,914Source | — | 9,822Source | 37,724Source | 41,037Source | 26,415Source | 10,268Source |
| Investment Income, InterestUSD | — | — | 84,539Source | 256,680Source | 913,663Source | 104,056Source | 717,168Source | 150,219Source | 555,526Source | 1,017,354Source | 572,006Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,585,692Source | -7,149,395Source | -11,557,002Source | -6,622,563Source | -10,086,687Source | -4,542,528Source | -29,438,613Source | -21,613,376Source | -15,426,048Source | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -84,987Source | -169,474Source | — |
| Nonoperating Income (Expense)USD | — | — | 84,539Source | 256,680Source | 913,663Source | 104,056Source | 717,168Source | 150,219Source | 555,526Source | 1,017,354Source | 572,006Source | -497Source |
| Operating ExpensesUSD | — | — | 7,662,509Source | 7,394,931Source | 12,456,343Source | 6,717,705Source | 10,803,855Source | 4,682,925Source | 29,956,415Source | 22,674,680Source | 16,141,113Source | 8,218,948Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 107,392,716Source | 15,946,078Source | 15,520,510Source | 2,913,750Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 33,532Source | — | 6,342Source | — | 2,618Source | — |
| Income Taxes Paid, Net | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -7,662,509Source | -7,394,931Source | -12,456,343Source | -6,717,705Source | -10,803,855Source | -4,682,925Source | -29,956,415Source | -22,674,680Source | -16,141,113Source | -8,218,948Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -7,577,970Source | -7,138,251Source | -11,542,680Source | -6,613,649Source | -10,086,687Source | -4,532,706Source | -29,400,889Source | -21,657,326Source | -15,569,107Source | -8,219,445Source |
| Income Tax Expense (Benefit)USD | — | — | 7,722Source | 11,144Source | 14,322Source | 8,914Source | — | 9,822Source | 37,724Source | 41,037Source | 26,415Source | 10,268Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -84,987Source | -169,474Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,585,692Source | -7,149,395Source | -11,557,002Source | -6,622,563Source | -10,086,687Source | -4,542,528Source | -29,438,613Source | -21,613,376Source | -15,426,048Source | — |
| Earnings Per Share, BasicUSD per share | — | — | -0.24Source | -0.24Source | -0.18Source | -0.22Source | -0.18Source | -0.15Source | -0.89Source | -0.76Source | -0.89Source | -0.59Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.24Source | -0.24Source | -0.18Source | -0.22Source | -0.18Source | -0.15Source | -0.89Source | -0.76Source | -0.89Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 31,926,651Source | 29,424,444Source | 63,771,377Source | 29,983,764Source | 55,369,123Source | 29,701,080Source | 32,965,706Source | 28,285,637Source | 17,341,146Source | 13,887,309Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 31,926,651Source | 29,424,444Source | 63,771,377Source | 29,983,764Source | 55,369,123Source | 29,701,080Source | 32,965,706Source | 28,285,637Source | 17,341,146Source | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,078,378Source | 2,949,403Source | 7,123,171Source | 2,745,247Source | 4,823,378Source | 2,707,851Source | 13,697,817Source | 11,381,978Source | 7,406,082Source | 4,023,170Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -29,101,560Source | -20,114,816Source | 13,952,065Source | 7,741,995Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 497Source |
| Investment Income, InterestUSD | — | — | 84,539Source | 256,680Source | 913,663Source | 104,056Source | 717,168Source | 150,219Source | 555,526Source | 1,017,354Source | 572,006Source | — |
| Nonoperating Income (Expense)USD | — | — | 84,539Source | 256,680Source | 913,663Source | 104,056Source | 717,168Source | 150,219Source | 555,526Source | 1,017,354Source | 572,006Source | -497Source |
| Operating ExpensesUSD | — | — | 7,662,509Source | 7,394,931Source | 12,456,343Source | 6,717,705Source | 10,803,855Source | 4,682,925Source | 29,956,415Source | 22,674,680Source | 16,141,113Source | 8,218,948Source |
| Research and Development ExpenseUSD | — | — | 4,584,131Source | 4,445,528Source | 5,333,172Source | 3,972,458Source | 5,980,477Source | 1,975,074Source | 16,258,598Source | 11,292,702Source | 8,735,031Source | 4,195,778Source |
Offerings
Registration 333-292665
Filing attachments
ex99-1.htm · 8-K · 2026-11-12
Exhibit 99.1 Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress - Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement - - Interim NEXICART-2 clinical trial results selected for oral presentation at ASH 2026 - LOS ANGELES, November 12, 2026 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (“Immix”, the “Company”, “we” or “us”),…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-30
Exhibit 99.1 Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, September 29, 2026 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $12…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-29
Exhibit 99.1 Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis - 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) - - To-date, all patients achieving MRD-negativity reached CR within one year…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-21
EX-99.1 4 ex99-1.htm EX-99.1 Exhibit 99.1 Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock LOS ANGELES, CA, May 21, 2026 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before de…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Immix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing - - No relapses to-date observed for patients who have reached CR - - All subsequently enrolled patients for who…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - Full enrollment of BLA-enabling trial complete, per prior guidance - - Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch - - Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission - LOS ANGELES, March 30, 2026 (GLOBE …
Read attachment ↗